Completed PHASE2 INTERVENTIONAL 2-arm NCT00913796

Metabolic Acidosis in Renal Transplant Patients (MART)

Metabolic Acidosis and Its Impact on Mineral Metabolism and Physical Performance in Renal Transplant Patients

Sponsor: Swiss Federal Institute of Technology

Conditions Bone Disease Metabolic Acidosis Mineral Metabolism Physical Capacity Renal Transplant Patients

Interventions Potassium chloride Potassium citrate

Updated 5 times since 2017 Last updated: Oct 21, 2010 Started: Dec 31, 2007 Primary completion: Mar 31, 2010 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00913796, this PHASE2 trial focuses on Bone Disease and Metabolic Acidosis and remains completed. Sponsored by Swiss Federal Institute of Technology, it has been updated 5 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Swiss Federal Institute of Technology
University of Texas Southwestern Medical Center
University of Zurich

Data source: University of Zurich

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zurich, Switzerland